Last reviewed · How we verify
Mifepristone tablets
Mifepristone is a progesterone receptor antagonist that blocks progesterone signaling, preventing pregnancy establishment and maintenance.
Mifepristone is a progesterone receptor antagonist that blocks progesterone signaling, preventing pregnancy establishment and maintenance. Used for Medical termination of intrauterine pregnancy of up to 49 days gestation (in combination with misoprostol).
At a glance
| Generic name | Mifepristone tablets |
|---|---|
| Sponsor | China Resources Zizhu Pharmaceutical Co., Ltd. |
| Drug class | Progesterone receptor antagonist |
| Target | Progesterone receptor (PR) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Health / Gynecology |
| Phase | FDA-approved |
Mechanism of action
Mifepristone competitively binds to progesterone receptors in the uterus and other tissues, blocking the effects of endogenous progesterone. This leads to endometrial breakdown and detachment of the conceptus, resulting in pregnancy termination when used in the early stages of pregnancy. It is typically used in combination with a prostaglandin analog (such as misoprostol) to enhance efficacy.
Approved indications
- Medical termination of intrauterine pregnancy of up to 49 days gestation (in combination with misoprostol)
Common side effects
- Vaginal bleeding/hemorrhage
- Abdominal pain/cramping
- Nausea
- Vomiting
- Diarrhea
- Dizziness
- Headache
Key clinical trials
- A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer (PHASE2)
- A Real-World Study Comparing the Efficacy of Different Treatment Regimens for Early Missed Abortion (NA)
- Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST) (PHASE4)
- REVERSE: Improving Treatment-resistant Post Traumatic Stress Disorder (PTSD) with Glucocorticoid Receptor (GR) Antagonism (PHASE2)
- Endometrial Transcript Profile with Progesterone After Post-ovulatory Mifepristone (EARLY_PHASE1)
- Assessing the Efficacy and Acceptability of Two Missed Period Pills Regimens (PHASE2, PHASE3)
- Comparison Between Letrozole and Mifepristone in Medical Termination of First Trimester Miscarriages (PHASE3)
- Mifepristone and Two Doses of Misoprostol for Abortion at 11&12 Weeks (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |